This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Dec 2011

Abbott & Reata Ink Deal for AIMs

Abbott and Reata will equally share costs and profits for all new AIMs in all newly licensed indications, except for rheumatoid arthritis and select other autoimmune diseases.

Abbott and Reata Pharmaceuticals have established a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs).


The agreement is in addition to the partnership between the two companies announced in September 2010 in which Reata granted to Abbott exclusive rights to develop and commercialize its lead AIM compound, bardoxolone methyl, outside of the U.S., excluding certain Asian markets. Bardoxolone methyl is currently in Phase III trials.


The new agreement is global and includes a large number of molecules in a broad range of therapeutic areas, including pulmonary, central nervous system disorders and immunology.


Related News